Answer
Yes, severe immune-related pneumonitis or interstitial lung disease, including a fatal case, has been observed with nivolumab + relatlimab.
Sources for this answer
- Opdualag 240 mg/80 mg concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 5Document updated
Sources checked